trending Market Intelligence /marketintelligence/en/news-insights/trending/GSSfv8a1u9gGYLT6C5KWdQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Microsoft, Oxford BioMedica team up to improve manufacturing of gene therapies

Paypal Well-Positioned To Gain Share In COVID-Related Digital Payments Shift

Possible Effects Of COVID-19 Crisis On Broadcast Networks

5G To Buoy Declining Smartphone Shipments Through 2024 Despite COVID-19 Effects

Online Video Households Poised To Overtake Multichannel In US Forecast

Microsoft, Oxford BioMedica team up to improve manufacturing of gene therapies

Microsoft Corp. entered into a research and development partnership with Oxford BioMedica PLC to help improve the quantity and quality of the company's gene therapy vectors using cloud and machine learning technologies.

SNL Image

Oxford BioMedica manufactures lentiviral vectors, which have the ability to deliver genetic information into a cell. These vectors are used in chimeric antigen receptor T-cell, or CAR-T cell therapies that reinfuse modified immune cells of the patient to fight or prevent disease.

Oxford BioMedica supplied vectors to Novartis AG for Kymriah, which has been approved by the European Commission and the U.S. Food and Drug Administration to treat certain types of blood cancer.

Under the two-year collaboration, the Oxford, U.K.-based biotechnology company will provide large data sets for analysis using Microsoft's Azure, a cloud computing service. Microsoft will use the data to develop computer simulation models and new algorithms to help with the development of the next generation of treatments.